Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace Inc (NPCE) is a pioneering medical technology company developing brain-responsive neuromodulation systems for epilepsy treatment. This page serves as the definitive source for official company announcements, financial updates, and clinical progress reports.
Access timely updates on NPCE's innovative RNS System, including FDA regulatory milestones, partnership developments with leading epilepsy centers, and peer-reviewed clinical study results. Investors will find earnings reports and strategic initiatives, while healthcare professionals can track real-world treatment outcomes and technological refinements.
Our curated news collection features:
- Quarterly financial performance updates
- RNS System enhancement announcements
- Clinical trial data publications
- Regulatory clearance milestones
- Research collaborations with medical institutions
Bookmark this page for structured access to NPCE's evolving role in neurotechnology and epilepsy care innovation.
NeuroPace reported a 28% year-over-year revenue increase to $21.1 million in Q3 2024, driven by higher RNS System sales. The company raised its full-year 2024 revenue guidance to $78-80 million. Gross margin was strong at 73.2%. Cash burn decreased to $1.8 million, with an increase in cash and short-term investments to $56.8 million. Operating expenses rose to $19.7 million, primarily due to increased R&D and SG&A costs. Net loss narrowed to $5.5 million from $7.3 million in Q3 2023. Management highlighted positive three-year data from a Post-Approval Study and announced an investor day in Q1 2025.
NeuroPace has submitted three-year safety and effectiveness data from its Post-Approval Study (PAS) of the RNS System to the FDA. The study, involving over 300 patients from more than 30 Level 4 Comprehensive Epilepsy Centers in the US, is the largest prospective trial in neuromodulation for drug-resistant focal epilepsy. The RNS System is the only neuromodulation device that provides stimulation and monitors patient response over time. The study will continue to a five-year follow-up endpoint as part of the system's initial FDA approval.
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, has announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company's management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors can access a live and archived webcast of the event at the provided link. Those interested in participating via telephone can dial +1-877-407-3982 and reference Conference ID 13749123. The webcast will be archived on the company's investor relations website for at least 90 days after the event.
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, has appointed Amy Treadwell as its new Vice President of Human Resources. CEO Joel Becker emphasized the importance of this appointment in supporting the company's growth and capitalizing on commercial, operating, and technological opportunities. Ms. Treadwell brings significant experience from healthcare and technology roles, having previously served as VP of People at CyCognito and held HR leadership positions at Carbon Health, Fitbit, and eBay.
This appointment, along with recent additions of Brett Wingeier as VP of Research and Development and Katie Keller as VP of Marketing, aims to strengthen NeuroPace's management team and enhance its strategy to increase access, adoption, and utilization of RNS therapy. Ms. Treadwell holds a Juris Doctor degree from Santa Clara University School of Law and a Bachelor's degree in International Relations from the University of Southern California.
NeuroPace (NPCE) has strengthened its management team with two key appointments. Brett Wingeier joins as the new Vice President of Research and Development, bringing over 20 years of experience in neurotech and biomedical engineering, including a decade as a key contributor to the development of NeuroPace's RNS System. Katie Keller has been appointed as the new Vice President of Marketing, bringing significant experience in medical device marketing, particularly from her role leading the global commercial marketing for Boston Scientific's Neuromodulation Deep Brain Stimulation franchise.
These appointments aim to enhance NeuroPace's market development programs, drive broader adoption of RNS therapy, and advance the company's strategy to expand the capabilities of the RNS System. Both executives express excitement about joining NeuroPace and contributing to its mission of transforming the lives of people living with epilepsy.
NeuroPace (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, has announced its participation in two upcoming healthcare investor conferences in September. The company will:
- Host one-on-one meetings with investors at the Lake Street Big8 Best Ideas Growth Conference on September 12th in New York
- Present at the Cantor Global Healthcare Conference from September 17th-19th in New York, featuring a fireside chat with CEO Joel Becker and CFO Rebecca Kuhn on September 18th at 11:30am ET
The fireside chat will be available via live webcast and a replay will be accessible on NeuroPace's Investor website. These conferences provide opportunities for NeuroPace to engage with investors and showcase its innovations in epilepsy treatment.
NeuroPace (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, has announced its participation in two major healthcare conferences this September. The company will:
- Attend the Wells Fargo 2024 Healthcare Conference on September 4 in Boston, hosting one-on-one investor meetings
- Present at the Morgan Stanley 22nd Annual Global Healthcare Conference from September 4-6 in New York
At the Morgan Stanley conference, CEO Joel Becker and CFO Rebecca Kuhn will participate in a fireside chat on September 6 at 8:30am ET, which will be webcast live. They will also host one-on-one investor meetings. A replay of the fireside chat will be available on NeuroPace's Investor website.
NeuroPace (NPCE) reported strong Q2 2024 financial results, with revenue growing 17% to $19.3 million compared to Q2 2023. The company increased its full-year 2024 revenue guidance to $76-$78 million. Key highlights include:
- Expanded gross margin to 73.4% from 72.5% in Q2 2023
- Decreased cash burn to $4.0 million from $4.4 million in Q2 2023
- Completed initial hiring of expanded commercial organization
- Continued progress in executing growth strategy, including expanding commercial organization and increasing active prescribing epileptologists
NeuroPace remains focused on generating broader adoption of RNS therapy and closing the treatment gap for drug-resistant epilepsy patients.
NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment, has announced its plans to release second quarter 2024 financial results on August 13, 2024, after market close. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results.
Investors can access the live webcast at https://viavid.webcasts.com/starthere.jsp?ei=1677457&tp_key=a97b4f856d or join via telephone by dialing +1-877-407-3982 (Conference ID: 13747326). The webcast will be archived on NeuroPace's investor relations website for at least 90 days after the event.
NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment, announced its participation in two healthcare conferences in May 2024. The company will join the Wells Fargo 2024 West Coast MedTech Tour on May 28 at 2:30pm PT in Menlo Park, CA, featuring a fireside chat with investors.
Additionally, NeuroPace will present at the Leerink Partners Healthcare Crossroads Conference from May 28-30 in Austin, TX. CEO Joel Becker will deliver a corporate presentation on May 30 at 8:00am CT, and the company will engage in one-on-one meetings with investors. The presentation will be available via live webcast and replay on NeuroPace’s Investor website.
